It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
SARS-CoV-2, the pathogenic agent of COVID-19, employs angiotensin converting enzyme-2 (ACE2) as its cell entry receptor. Clinical data reveal that in severe COVID-19, SARS-CoV-2 infects the lung, leading to a frequently lethal triad of respiratory insufficiency, acute cardiovascular failure, and coagulopathy. Physiologically, ACE2 plays a role in the regulation of three systems that could potentially be involved in the pathogenesis of severe COVID-19: the kinin–kallikrein system, resulting in acute lung inflammatory edema; the renin–angiotensin system, promoting cardiovascular instability; and the coagulation system, leading to thromboembolism. Here we assembled a healthy human lung cell atlas meta-analysis with ~ 130,000 public single-cell transcriptomes and show that key elements of the bradykinin, angiotensin and coagulation systems are co-expressed with ACE2 in alveolar cells and associated with their differentiation dynamics, which could explain how changes in ACE2 promoted by SARS-CoV-2 cell entry result in the development of the three most severe clinical components of COVID-19.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Ferruzzi, Adriano J 3
; Skaf, Munir S 3
; Velander, William H 4 ; Araujo, Eliana P 2 ; Velloso, Licio A 5 1 University of Campinas, Laboratory of Cell Signaling, Obesity and Comorbidities Research Center, Instituto de Biologia - Bloco Z. Campus Universitário Zeferino Vaz, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); University of Campinas, Physician-Scientist Graduate Program, School of Medical Sciences, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494)
2 University of Campinas, Laboratory of Cell Signaling, Obesity and Comorbidities Research Center, Instituto de Biologia - Bloco Z. Campus Universitário Zeferino Vaz, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); University of Campinas, Nursing School, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494)
3 University of Campinas, Institute of Chemistry and Center for Computing in Engineering and Sciences, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494)
4 University of Nebraska, Department of Chemical and Biomolecular Engineering, Lincoln, USA (GRID:grid.24434.35) (ISNI:0000 0004 1937 0060)
5 University of Campinas, Laboratory of Cell Signaling, Obesity and Comorbidities Research Center, Instituto de Biologia - Bloco Z. Campus Universitário Zeferino Vaz, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494)




